Diabetes Risk Assessment Profile Test
50+ booked in last 3 daysDiabetes Risk Assessment Test Overview
Diabetes is a metabolic disease that causes the blood sugar levels to increase beyond the reference range. Usually the fasting and post lunch levels are measured for diagnosis. Very often, by the time symptoms of diabetes occur, it is too late to diagnose and begin treatment as the damage has already started. Many of these patients have a family history or predisposing factors which may lead to diabetes mellitus. These patients can be diagnosed or treated early if risk assessment is already done prior.
Diabetes is a metabolic disease that occurs when the level of blood sugar in the body increase beyond the reference range. This can lead to a variety of symptoms like excess urination, increased hunger, and a fruity smell of urine.
There are two types of diabetes, Type 1 or diabetes insipidus and Type 2 or diabetes mellitus. Type 1 diabetes is an autoimmune disorder caused by the immune system attacking the pancreas, thus affecting the gland's ability to produce insulin. Type 2 diabetes however is due to the patient's lifestyle, making it both preventable and reversible with proper management. However, by the time patients seek a diagnosis, the damage has already begun. Patients can be diagnosed or treated early if they have a risk assessment done early. The risk test is a blood test that measures glycated haemoglobin levels, fasting blood by fasting insulin ratio (HOMA index) and adiponectin levels in the blood.
Why is a Diabetes Risk Assessment Profile Done?
The test is done to assess patients who are at risk of developing diabetes due to certain predisposing factors. These include:
- Family history of diabetes in first-degree relatives:
It is always better to get a risk assessment done especially if immediate family members have been diagnosed with diabetes previously. - Genetics:
Certain genetic factors like insulin antibodies and insulin resistance contribute to insulin resistance in an individual. Insulin resistance refers to the inability of the body to react to the effects of the insulin hormone. - Obesity:
Bodies with BMI > 25 are considered morbidly obese, which increases the risk of insulin resistance and hence diabetes.
The diabetes risk assessment profile is suggested for people who have:
- Family history of diabetes
- Sedentary lifestyle
- Smoking
- Morbid obesity
- Excess thirst
- Frequent urination
- Increased appetite
- Sudden weight loss
- Frequent mood swings
- Fruity-smelling breath
- Blurry vision
- Increased fatigued
- Yeast infections
- Slow healing of wounds
Written by: Dr.Shibani R, Medical Writer, Medical Affairs
Diabetes Risk Assessment Profile Test Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the Diabetes Risk Assessment Profile Test with a clear pricing structure.
The Diabetes Risk Assessment Profile Test Price in Mumbai is ₹ 3,045 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
Diabetes risk assessment test is done to assess patients who are a risk of developing diabetes due to certain predisposing factors. These include:
- Positive family history of diabetes in the first degree relatives.
- Certain genetic factors (Insulin antibodies, insulin resistance )
- Obesity.
-
The risk profile is done to assess the possibility that one may develop diabetes with an immediate risk.
Diabetes risk assessment test measures glycated haemoglobin levels, fasting blood by fasting insulin ratio (HOMA index) and adiponectin levels in blood.
Diabetes risk assessment test requires a blood sample. A tourniquet (elastic) band is placed tightly on the upper arm. The patient is then asked to make a fist. This helps in the build-up of blood filling the veins. The skin is disinfected before needle insertion and the blood sample is collected in vacutainer.
HbA1C levels of > 6.5% are classified as diabetics. Those with HbA1c between 5.7 to 6.4 % are prediabetes that is at risk of developing diabetes.
Adiponectin factor indicates risk of obesity and metabolic diseases. Low levels indicates risk of developing diabetes due to obesity, other risk factors and indicated towards development of insulin resistance
HOMA index ( FBS/Fasting Insulin) indicates the risk of developing diabetes to due high insulin resistance. High index indicates higher predisposition to type 2 diabetes mellitus.
For a fasting blood sugar (FBS) test, a fasting period of 8-12 hours is recommended. For the glucose postprandial test (Glucose PP), the test needs to be done 2 hours after the start of the meal.
For glycated Hb1Ac,
-
- Excellent Control - 6 to 7%,
- Fair to Good Control - 7 to 8%,
- Unsatisfactory Control - 8 to 10%,
- Poor Control - More than 10%
For glucose fasting,
-
- Normal: 99 mg/dL or lower
- Prediabetes: 100 to 125 mg/dL
- Diabetes: 126 mg/dL or higher
Following tests are often ordered along with the diabetes profile, mini test:
- Lipid Profile
- Thyroid profile Total
- Vitamin D (25-OH)
- Glucose - Postprandial
- Complete Blood Count
- Vitamin B12
- Liver Function Test
- Kidney Function Test
- Urine Routine & Microscopy
- Kidney Function Test with Electrolytes
References:
Diabetes Risk Profile
Diabetes Screening Test
HOMA index
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Fasting Blood Sugar (FBS)
Insulin
Adiponectin
Glycosylated hemoglobin (HBA1c)
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.